CURE241220C101000
- 5.35
- 0.000.00%
Direxion Daily Healthcare Bull 3X Shares Newsroom
Wednesday Ends With Index Decline | Wall Street Today
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
'Bunker' and 'Booster' Stocks in the U.S. – Which Would Perform Better in a Downturn Vs. Upturn?
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
UnitedHealth Group Analyst Ratings
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Tradepulse Power Inflow Alert: Eli Lilly & Company Climbs Over 22 Points After Alert
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Judge Denies Abbott Request for Retrial, Lower Damages in $500M Baby Formula Case
Amgen's weight loss drug has a remarkable 20% reduction effect, but with high side effects, causing the stock price to plummet by 12.3% at one point!
Although the weight loss effect of amgen's MariTide drug met expectations, the high side effects, lower than eli lilly and co's Zepbound, and the trial results falling below Wall Street's high expectations, led to amgen's stock price plunging over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk a/s, which benefited from the Biden policy rise at the same time. In a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with about 11% of patients dropping out of the trial due to side effects, higher than eli lilly's 7%.
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
Unpacking the Latest Options Trading Trends in Intuitive Surgical
The Biden administration has proposed covering weight loss medications under Medicare, while Trump's team may become the biggest obstacle.
①The Biden administration has proposed expanding the coverage of federal medical care and medical subsidies to include weight loss drugs; ②The White House claims that these drugs can prevent type 2 diabetes, lower the risk of cardiovascular diseases such as heart disease, but currently they are too expensive for Americans. ③This proposal may be blocked by the Trump administration taking office next year, as Senator Kennedy opposes weight loss drugs.
Intuitive Surgical Analyst Ratings
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
(ABBV) - Analyzing AbbVie's Short Interest
Eli Lilly Stock Is Rising Tuesday: What's Going On?
Anavex Gains After Seeking EU Marketing Nod for Alzheimer's Drug
FOMC meeting minutes incoming, US stock index futures show mixed movements | Highlights tonight
1. Intel has locked in $7.9 billion in US chip subsidies for advanced chip factories; 2. Rivian has secured a $6.6 billion conditional loan commitment from the US Department of Energy, planning to build in the US; 3. The Federal Reserve will release the minutes of the November meeting at 3 am Beijing time on Wednesday.